Kurv Yield Prem Strategy Tesla ETF (TSLP)
| Assets | $21.13M |
| Expense Ratio | 1.00% |
| PE Ratio | 120.49 |
| Shares Out | 1.04M |
| Dividend (ttm) | $6.15 |
| Dividend Yield | 30.19% |
| Ex-Dividend Date | Feb 4, 2026 |
| Payout Ratio | 3,637.68% |
| 1-Year Return | -3.55% |
| Volume | 16,096 |
| Open | 20.37 |
| Previous Close | 20.61 |
| Day's Range | 20.07 - 20.51 |
| 52-Week Low | 15.36 |
| 52-Week High | 26.52 |
| Beta | 1.41 |
| Holdings | 11 |
| Inception Date | Oct 27, 2023 |
About TSLP
Fund Home PageThe Kurv Yield Prem Strategy Tesla ETF (TSLP) is an exchange-traded fund that mostly invests in consumer discretionary equity. The fund seeks to provide current income and capped gains on the Tesla stock (TSLA) through a synthetic covered call strategy, collateralized by cash and short-term fixed-income instruments. The actively managed fund uses both standardized exchange-traded and FLEX options. TSLP was launched on Oct 27, 2023 and is issued by Kurv.
Top 10 Holdings
118.59% of assets| Name | Symbol | Weight |
|---|---|---|
| United States Treasury Bills 0% | B.0 06.11.26 | 39.14% |
| Tsla 03/20/2026 250 C | n/a | 30.24% |
| United States Treasury Bills 0% | B.0 03.19.26 | 28.79% |
| United States Treasury Bills 0% | B.0 09.03.26 | 23.75% |
| Tsla 03/20/2026 450 C | n/a | 10.33% |
| Fidelity Government Portfolio | FIGXX | 2.47% |
| Tsla 03/20/2026 380 P | n/a | 0.84% |
| OTHER ASSETS AND LIABILITIES | n/a | -0.05% |
| Tsla 02/27/2026 420 C | n/a | -0.26% |
| Cash Offset | n/a | -16.65% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Feb 4, 2026 | $0.500 | Feb 5, 2026 |
| Jan 7, 2026 | $0.500 | Jan 8, 2026 |
| Dec 3, 2025 | $0.500 | Dec 4, 2025 |
| Nov 5, 2025 | $0.500 | Nov 6, 2025 |
| Oct 8, 2025 | $0.500 | Oct 9, 2025 |
| Sep 3, 2025 | $0.450 | Sep 4, 2025 |
News
Kurv Investment Management Completes Reorganization of Yield Premium Suite to Proprietary Trust
SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Su...
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Soci...